Friday – Clinical Track 2A

Name Badge ID(Required)

Full Name(Required)

Enter your first and last names as you would like them to appear on your certificates.

First Last

Email(Required)

Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

Overall Evaluation

	Excellent	Good	Fair	Poor
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)

Presentation free of commercial bias?

	Yes	No
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)

If you answered “No, this presentation was not free of commercial bias”, on any of the above, please explain your reason(s).

Applicable to my practice/research

	Yes	No
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)

This activity should improve my

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Comments